Related Experiment Video
Updated: Mar 16, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549
Xian-Hui Wang1, Yao Lu1, Jing-Jing Liang1
1Department of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, PR China.
Abstract:
MicroRNAs (miRNAs) are potent post-transcriptional regulators of gene expression and play roles in DNA damage response (DDR). PLK1 is identified as a modulator of DNA damage checkpoint. Although down-regulation of PLK1 by certain microRNAs has been reported, little is known about the interplay between PLK1 and miR-509-3-5p in DDR. Here we have demonstrated that miR-509-3-5p repressed PLK1 expression by targeting PLK1 3'-UTR, thereby causing mitotic aberration and growth arrest of human lung cancer A549 cells. Repression of PLK1 by miR-509-3-5p was further evidenced by over-expression of miR-509-3-5p in A549, HepG2 and HCT116p53(-/-) cancer cells, in which PLK1 protein was suppressed. Consistently, miR-509-3-5p was stimulated, while PLK1 protein was down-regulated in A549 cells exposed to CIS and ADR, suggesting that suppression of PLK1 by miR-509-3-5p is a component of CIS/ADR-induced DDR pathway. Flow cytometry and immunofluorescence labeling showed that over-expression of miR-509-3-5p in A549 induced G2/M arrest and aberrant mitosis characterized by abnormal bipolar mitotic spindles, condensed chromosomes, lagging DNA and chromosome bridges. In addition, over-expression of miR-509-3-5p markedly blocked A549 cell proliferation and sensitized the cells to CIS and ADR treatment. Taken together, miR-509-3-5p is a feasible suppressor for cancer by targeting PLK1. Our data may provide aid in potential design of combined chemotherapy and in our better understanding of the roles of microRNAs in response to DNA damage.
Insights
MicroRNA 509-3-5p suppresses lung cancer growth by targeting PLK1, a key player in DNA damage response. This finding offers potential for combined cancer therapies.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- MicroRNAs (miRNAs) regulate gene expression and are involved in DNA damage response (DDR).
- PLK1 is a known modulator of DNA damage checkpoints.
- The specific interaction between miR-509-3-5p and PLK1 in DDR remains largely unexplored.
Purpose of the Study:
- To investigate the role of miR-509-3-5p in the DNA damage response pathway.
- To elucidate the mechanism by which miR-509-3-5p affects PLK1 expression.
- To evaluate the potential of miR-509-3-5p as a therapeutic target in human lung cancer.
Main Methods:
- Overexpression of miR-509-3-5p in human cancer cell lines (A549, HepG2, HCT116p53(-/-)).
- Target validation using 3'-UTR reporter assays.
- Cell cycle analysis via flow cytometry.
- Mitotic spindle morphology assessment using immunofluorescence labeling.
- Assessment of cell proliferation and chemosensitivity.
Main Results:
- miR-509-3-5p directly targets the 3'-UTR of PLK1, repressing its expression.
- Overexpression of miR-509-3-5p in cancer cells led to suppressed PLK1 protein levels.
- miR-509-3-5p induction in cells exposed to cisplatin (CIS) and adriamycin (ADR) correlated with PLK1 downregulation, indicating its role in CIS/ADR-induced DDR.
- miR-509-3-5p overexpression caused G2/M phase arrest and aberrant mitosis in A549 cells.
- miR-509-3-5p significantly inhibited A549 cell proliferation and enhanced sensitivity to CIS and ADR.
Conclusions:
- miR-509-3-5p acts as a tumor suppressor by targeting PLK1.
- The miR-509-3-5p/PLK1 axis is a crucial component of the DNA damage response pathway.
- These findings support the potential development of miR-509-3-5p-based strategies for combined cancer chemotherapy.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
MicroRNAs

